Selected research
Industry Research
Oral Anti-Diabetic Drug Industry Research Report 2026
Market perspective
The global Oral Anti-Diabetic Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Oral Anti-Diabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Oral Anti-Diabetic Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Oral Anti-Diabetic Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Oral Anti-Diabetic Drug include Astellas, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Merck And Co., AstraZeneca, Pfizer, Eli Lilly and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Oral Anti-Diabetic Drug market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oral Anti-Diabetic Drug Market by Company
Astellas
Biocon
Boehringer Ingelheim
Bristol Myers Squibb
Merck And Co.
AstraZeneca
Pfizer
Eli Lilly
Novartis
Sanofi
Takeda
Abbott
Janssen Pharmaceuticals
Oral Anti-Diabetic Drug Segment by Type
Gliclazide
Glimepiride
Glyburide
Others
Oral Anti-Diabetic Drug Segment by Application
Hospital
Research Institual
Oral Anti-Diabetic Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Anti-Diabetic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Anti-Diabetic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Anti-Diabetic Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Oral Anti-Diabetic Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Oral Anti-Diabetic Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Oral Anti-Diabetic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Gliclazide
- Glimepiride
- Glyburide
- Others
Applications
- Hospital
- Research Institual
Companies covered
- Astellas
- Biocon
- Boehringer Ingelheim
- Bristol Myers Squibb
- Merck And Co.
- AstraZeneca
- Pfizer
- Eli Lilly
- Novartis
- Sanofi
- Takeda
- Abbott
- Janssen Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Oral Anti-Diabetic Drug Market Size (2021-2032)
- 2.2.2 Global Oral Anti-Diabetic Drug Sales (2021-2032)
- 2.2.3 Global Oral Anti-Diabetic Drug Market Average Price (2021-2032)
- 2.3 Oral Anti-Diabetic Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Gliclazide
- 2.3.3 Glimepiride
- 2.3.4 Glyburide
- 2.3.5 Others
- 2.4 Oral Anti-Diabetic Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Research Institual
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Oral Anti-Diabetic Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Oral Anti-Diabetic Drug Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Oral Anti-Diabetic Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Oral Anti-Diabetic Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Oral Anti-Diabetic Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Oral Anti-Diabetic Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Oral Anti-Diabetic Drug, Product Type & Application
- 3.8 Global Manufacturers of Oral Anti-Diabetic Drug, Established Date
- 3.9 Global Oral Anti-Diabetic Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Astellas
- 4.1.1 Astellas Company Information
- 4.1.2 Astellas Business Overview
- 4.1.3 Astellas Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Astellas Oral Anti-Diabetic Drug Product Portfolio
- 4.1.5 Astellas Recent Developments
- 4.2 Biocon
- 4.2.1 Biocon Company Information
- 4.2.2 Biocon Business Overview
- 4.2.3 Biocon Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biocon Oral Anti-Diabetic Drug Product Portfolio
- 4.2.5 Biocon Recent Developments
- 4.3 Boehringer Ingelheim
- 4.3.1 Boehringer Ingelheim Company Information
- 4.3.2 Boehringer Ingelheim Business Overview
- 4.3.3 Boehringer Ingelheim Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Boehringer Ingelheim Oral Anti-Diabetic Drug Product Portfolio
- 4.3.5 Boehringer Ingelheim Recent Developments
- 4.4 Bristol Myers Squibb
- 4.4.1 Bristol Myers Squibb Company Information
- 4.4.2 Bristol Myers Squibb Business Overview
- 4.4.3 Bristol Myers Squibb Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bristol Myers Squibb Oral Anti-Diabetic Drug Product Portfolio
- 4.4.5 Bristol Myers Squibb Recent Developments
- 4.5 Merck And Co.
- 4.5.1 Merck And Co. Company Information
- 4.5.2 Merck And Co. Business Overview
- 4.5.3 Merck And Co. Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck And Co. Oral Anti-Diabetic Drug Product Portfolio
- 4.5.5 Merck And Co. Recent Developments
- 4.6 AstraZeneca
- 4.6.1 AstraZeneca Company Information
- 4.6.2 AstraZeneca Business Overview
- 4.6.3 AstraZeneca Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AstraZeneca Oral Anti-Diabetic Drug Product Portfolio
- 4.6.5 AstraZeneca Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Oral Anti-Diabetic Drug Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly Oral Anti-Diabetic Drug Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 Novartis
- 4.9.1 Novartis Company Information
- 4.9.2 Novartis Business Overview
- 4.9.3 Novartis Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novartis Oral Anti-Diabetic Drug Product Portfolio
- 4.9.5 Novartis Recent Developments
- 4.10 Sanofi
- 4.10.1 Sanofi Company Information
- 4.10.2 Sanofi Business Overview
- 4.10.3 Sanofi Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sanofi Oral Anti-Diabetic Drug Product Portfolio
- 4.10.5 Sanofi Recent Developments
- 4.11 Takeda
- 4.11.1 Takeda Company Information
- 4.11.2 Takeda Business Overview
- 4.11.3 Takeda Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Takeda Oral Anti-Diabetic Drug Product Portfolio
- 4.11.5 Takeda Recent Developments
- 4.12 Abbott
- 4.12.1 Abbott Company Information
- 4.12.2 Abbott Business Overview
- 4.12.3 Abbott Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Abbott Oral Anti-Diabetic Drug Product Portfolio
- 4.12.5 Abbott Recent Developments
- 4.13 Janssen Pharmaceuticals
- 4.13.1 Janssen Pharmaceuticals Company Information
- 4.13.2 Janssen Pharmaceuticals Business Overview
- 4.13.3 Janssen Pharmaceuticals Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Janssen Pharmaceuticals Oral Anti-Diabetic Drug Product Portfolio
- 4.13.5 Janssen Pharmaceuticals Recent Developments
5 Global Oral Anti-Diabetic Drug Market Scenario by Region
- 5.1 Global Oral Anti-Diabetic Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Oral Anti-Diabetic Drug Sales by Region: 2021-2032
- 5.2.1 Global Oral Anti-Diabetic Drug Sales by Region: 2021-2026
- 5.2.2 Global Oral Anti-Diabetic Drug Sales by Region: 2027-2032
- 5.3 Global Oral Anti-Diabetic Drug Revenue by Region: 2021-2032
- 5.3.1 Global Oral Anti-Diabetic Drug Revenue by Region: 2021-2026
- 5.3.2 Global Oral Anti-Diabetic Drug Revenue by Region: 2027-2032
- 5.4 North America Oral Anti-Diabetic Drug Market Facts & Figures by Country
- 5.4.1 North America Oral Anti-Diabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 5.4.3 North America Oral Anti-Diabetic Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Oral Anti-Diabetic Drug Market Facts & Figures by Country
- 5.5.1 Europe Oral Anti-Diabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 5.5.3 Europe Oral Anti-Diabetic Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Oral Anti-Diabetic Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Oral Anti-Diabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Oral Anti-Diabetic Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Oral Anti-Diabetic Drug Market Facts & Figures by Country
- 5.7.1 South America Oral Anti-Diabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 5.7.3 South America Oral Anti-Diabetic Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Oral Anti-Diabetic Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Oral Anti-Diabetic Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Oral Anti-Diabetic Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Oral Anti-Diabetic Drug Sales by Type (2021-2032)
- 6.1.1 Global Oral Anti-Diabetic Drug Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Oral Anti-Diabetic Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Oral Anti-Diabetic Drug Revenue by Type (2021-2032)
- 6.2.1 Global Oral Anti-Diabetic Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Oral Anti-Diabetic Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Oral Anti-Diabetic Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Oral Anti-Diabetic Drug Sales by Application (2021-2032)
- 7.1.1 Global Oral Anti-Diabetic Drug Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Oral Anti-Diabetic Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Oral Anti-Diabetic Drug Revenue by Application (2021-2032)
- 7.2.1 Global Oral Anti-Diabetic Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Oral Anti-Diabetic Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Oral Anti-Diabetic Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Oral Anti-Diabetic Drug Value Chain Analysis
- 8.1.1 Oral Anti-Diabetic Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Oral Anti-Diabetic Drug Production Mode & Process
- 8.2 Oral Anti-Diabetic Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Oral Anti-Diabetic Drug Distributors
- 8.2.3 Oral Anti-Diabetic Drug Customers
9 Global Oral Anti-Diabetic Drug Analyzing Market Dynamics
- 9.1 Oral Anti-Diabetic Drug Industry Trends
- 9.2 Oral Anti-Diabetic Drug Industry Drivers
- 9.3 Oral Anti-Diabetic Drug Industry Opportunities and Challenges
- 9.4 Oral Anti-Diabetic Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst